McDermott Will & Schulte advised Adcytherix, a biopharmaceutical company specializing in the design and development of proprietary antibody-drug conjugates (ADCs), on a €105 million Series A fundraising round to accelerate the development of its portfolio of next-generation ADCs.

The round was led by Bpifrance through its Large Venture and InnoBio funds, and co-led by Kurma Partners, Andera Partners, and Angelini Ventures, alongside a consortium of leading international investors, including Surveyor Capital (a Citadel company) and aMoon. The founders and historical investors also participated in the round.

This Series A round positions Adcytherix as one of the most promising players in the ADC field and will enable the company to advance its lead candidate, ADCX-020, into the clinical stage, with the filing of the first Investigational New Drug (IND) applications (US) and Clinical Trial Applications (CTA – EU, UK, and Canada) by the end of 2025. At the same time, Adcytherix will expand its portfolio of proprietary ADCs using innovative payloads.

The McDermott team on this transaction included:

• Emmanuelle Trombe, Partner, Lucie Martin, Counsel, and Pauline Orliange, Associate in Life Sciences
• Côme de Saint Vincent, Partner in tax law

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.